Black Diamond Therapeutics (BDTX) Equity Average (2019 - 2025)
Black Diamond Therapeutics' Equity Average history spans 5 years, with the latest figure at $119.2 million for Q4 2025.
- For Q4 2025, Equity Average rose 31.9% year-over-year to $119.2 million; the TTM value through Dec 2025 reached $119.2 million, up 31.9%, while the annual FY2025 figure was $97.7 million, N/A changed from the prior year.
- Equity Average reached $119.2 million in Q4 2025 per BDTX's latest filing, down from $129.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $294.3 million in Q1 2021 to a low of $90.4 million in Q4 2024.
- Average Equity Average over 3 years is $159.7 million, with a median of $129.4 million recorded in 2025.
- Peak YoY movement for Equity Average: surged 91.01% in 2021, then plummeted 30.46% in 2025.
- A 3-year view of Equity Average shows it stood at $235.0 million in 2021, then tumbled by 61.55% to $90.4 million in 2024, then skyrocketed by 31.9% to $119.2 million in 2025.
- Per Business Quant, the three most recent readings for BDTX's Equity Average are $119.2 million (Q4 2025), $129.4 million (Q3 2025), and $137.1 million (Q2 2025).